KyungDong Pharm Co., Ltd. will launch “Rotodipine Tablets,” a combination drug that can treat dyslipidemia and hypertension simultaneously, on June 2, 2025.
Rotodipine tablets are a product that combines Rosuvastatin, a treatment for dyslipidemia, and Amlodipine, a treatment for hypertension, into one tablet. It is characterized by improving treatment convenience and medication compliance by taking it once a day for patients suffering from both diseases.
Rosuvastatin is an HMG-CoA reductase inhibitor that effectively lowers LDL-C (low-density lipoprotein cholesterol), and amlodipine is a calcium channel blocker (CCB) that has vasodilating and blood pressure-lowering effects. Both ingredients are recommended as first-line treatments in domestic and international guidelines, and effective cardiovascular disease management is possible when used in combination.
Rotodipine tablets use rosuvastatin as the main ingredient, which has a better LDL-C lowering effect than the existing Atorvastatin/Amlodipine combination, and is expected to be an excellent alternative even for patient groups sensitive to treatment effects and drug efficacy.
In addition, it is released in three dosage groups (5/5mg, 10/5mg, 20/5mg), allowing the dosage to be adjusted depending on the patient's disease condition. It is a generic-based combination drug that takes both economics and medication convenience into consideration, making it especially suitable for middle-aged and elderly patients and long-term patients.
□ Product information
▶ Product name: Rotodipine tablets
▶ Ingredients/Content: Rosuvastatin 5/10/20mg + Amlodipine 5mg
▶ Efficacy/Effectiveness: Patients requiring simultaneous treatment of dyslipidemia and hypertension
▶ Usage/Dosage: Once a day, oral administration
▶ Packaging unit: 30 tablets/bottle
▶ Dosage form: Orange round film-coated tablet
※ Please refer to the product manual for other details such as precautions for use.